Earlier this month, US Senators Chuck Grassley, R-Iowa, and Amy Klobuchar, D-Minnesota, sent a letter to Federal Trade Commission (FTC) Chairman Joseph Simons urging the FTC to “examine whether makers of biologic medicines are using strategies like ‘pay-for-delay’ to hinder or delay biosimilars from entering the market.”
Earlier this month, US Senators Chuck Grassley, R-Iowa, and Amy Klobuchar, D-Minnesota, sent a letter to Federal Trade Commission (FTC) Chairman Joseph Simons urging the FTC to “examine whether makers of biologic medicines are using strategies like ‘pay-for-delay’ to hinder or delay biosimilars from entering the market.”
According to the letter, “Biologics play an important role in treating many serious illnesses and are among the fastest growing classes of therapeutic products… Without biosimilar competition, US patients and payers will likely see additional price increases on biologics in the years to come.”
The senators cite examples of alleged pay-for-delay strategies, specifically the settlement agreements that pharmaceutical company AbbVie has entered into with both Amgen and Samsung Bioepis over their adalimumab biosimilars, referenced on AbbVie’s originator product, Humira. The drug is the world’s top-selling prescription product, with annual sales of $16 billion.
Under each of the settlement agreements, Amgen and Samsung are unable to launch their biosimilars in the United States until 2023, but both products will be available for purchase on the European market as soon as the end of 2018.
“This means that while European patients will benefit from biosimilar competition later this year, Americans may be without access to Humira biosimilars for almost 5 more years. While such terms in patent settlement agreements may not always be inappropriate, the incentives for parties to delay biosimilar entry are present, and biologic markets could be susceptible to patent settlement abuse,” reads the letter.
Furthermore, this is not the first time that the FTC has been called on to investigate these very settlements. In April 2018, patient advocacy group Patients for Affordable Drugs (P4AD) also urged the FTC to examine the same agreement between AbbVie and Samsung.
“AbbVie is using pay-for-delay deals to keep a cheaper generic off the market and patients are the victims. We believe it is illegal and anti-competitive, and we are asking the FTC to step in and protect patients from AbbVie’s price hikes,” said the president and co-founder of P4AD, David Mitchell, in a statement.
Conversely, AbbVie has strongly opposed using the term “pay-for-delay” to describe the agreements. In a prior statement, the company said “AbbVie’s settlements with Amgen and Samsung Bioepis are in no way pay-for-delay arrangements. AbbVie is not paying Amgen or Samsung Bioepis, and in fact both Amgen and Samsung Bioepis will be paying royalties to AbbVie once their adalimumab biosimilar products launch in the [United States].”
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.